You searched for Antibody candidate - Page 32 of 69

News and Trends 30 Aug 2016

Top 10 Best-selling Biologicals of 2015

…price, managed to beat it. Humira is the tradename of adalimumab, an antibody that binds to TNFα and thus reduces inflammation. It’s prescribed for rheumatoid arthritis, psoriasis, Crohn’s and other…

August 30, 2016 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 1 Dec 2015

How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies

…trigger the cancerous B-cell to die by apoptosis. A. Bite antibody constructs are generated by genetically linking minimal binding domains of mAbs onto a single polypeptide chain. B. Antibody constructs…

December 1, 2015 - 3 minutesmins - By Eva Cosson

News and Trends 15 Sep 2016

Roche’s New Antibody is besting the best MS Drug

Roche is poised to blow away the competition for the new multiple sclerosis drug with its leading candidate, Ocrevus (ocrelizumab). Phase III data shows it outperforming Merck’s Rebif, the standard…

September 15, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 20 Jul 2018

Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema

…the safety and tolerability of a new kind of antibody treatment for diabetic macular edema. The trial focused on injecting the THR-317 antibody, which is directed against the human placental…

July 20, 2018 - 2 minutesmins - By External Contributor

morphosys genmab janssen cancer immunotherapy

News and Trends 28 Jan 2019

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

…to CD38 for the treatment of cancer, including multiple myeloma. MOR202 induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated killing of multiple myeloma cells. (Source: MorphoSys) With…

January 28, 2019 - 3 minutesmins - By Dani Bancroft

News and Trends 19 May 2016

FDA approves First ever antibody to target Cancer PD-L1

…Approval Program, and the positive decision was made after data from a Phase II trial (IMVigor 210). The candidate has shown to cause a tumor response in 26% (80 out…

May 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

argenx llama inspired antibodies cover cancer immunotherapy

News and Trends 5 Dec 2018

Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal

Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The Dutch company argenx’s antibodies have shown positive results in clinical trials, and have attracted Janssen…

December 5, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 12 Jan 2017

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

…JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment for respiratory syncytial…

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Oct 2016

Shooting for the Moon: German Biotech Acquired for a Record €1.3B

…in Germany. Astellas will pay €442M upfront and is offering up to an extra €860M pending the successful development of Ganymed’s pipeline lead candidate, IMAB362. The therapeutic antibody has orphan…

October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Aug 2016

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

Ablynx has disclosed ‘compelling’ results for its Phase IIb trial in rheumatoid arthritis. But it might have a hard time compelling AbbVie to pay €68M to continue the candidate’s development,…

August 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 26 Aug 2016

US Money Magnet get hands on UK Bispecific Antibodies for Neurodegenerative Disease

F-star’s “plug-and-play” technology can turn any existing antibody into a full-size bispecific antibody. Denali has recognized its potential use for drug delivery to the CNS and inked a deal with…

August 26, 2016 - 2 minutesmins - By Evelyn Warner

In Depth 15 May 2024

Drugs for IgA nephropathy on the rise in the clinic

…the kidneys against placebo in a phase 3 trial. The study is set to end next year. Moreover, Boston-based Alexion Pharmaceuticals’ monoclonal antibody ALXN1210, also known as ravulizumab is currently…

May 15, 2024 - 9 minutesmins - By Roohi Mariam Peter

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

Top 10 Best-selling Biologicals of 2015

How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies

Roche’s New Antibody is besting the best MS Drug

Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

FDA approves First ever antibody to target Cancer PD-L1

Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Shooting for the Moon: German Biotech Acquired for a Record €1.3B

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

US Money Magnet get hands on UK Bispecific Antibodies for Neurodegenerative Disease

Drugs for IgA nephropathy on the rise in the clinic

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!